Review
Open access
Aug 2026
Immune checkpoint inhibitors have changed the treatment landscape for gastric and gastroesophageal junction adenocarcinoma, yet durable benefit remains uneven across biomarker-defined groups. PD-L1 combined positive score, MSI/dMMR, tumor mutational burden, EBV status, HER2, and CLDN18.2 guide treatment eligibility, bu...
Zi-Qiang Ling, Renzhe Tang, B. Yuan et al.
· Frontiers in Immunology · 0 citations